• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Mirogabalin Side Effects in Spinal Stenosis Resolved in Most Trial Patients

by
November 19, 2026
in Health
Reading Time: 5 mins read
0
Mirogabalin Side Effects in Spinal Stenosis Resolved in Most Trial Patients

Mirogabalin Side Effects in Spinal Stenosis Resolved in Most Trial Patients

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A post hoc analysis of the randomized controlled MiroTAS trial has found that common adverse drug reactions associated with mirogabalin, specifically dizziness and somnolence, resolved or improved in the majority of treated patients experiencing lumbar spinal stenosis. The investigation examined data gathered from adult participants across 32 medical centers in Japan who received the oral gabapentinoid as an add-on therapy alongside nonsteroidal anti-inflammatory drugs. Across the study cohort, researchers tracked the emergence, clinical progression, and resolution timelines of treatment-emergent symptoms to understand how adverse events influence therapeutic persistence and daily disease management. The findings indicate that while central nervous system adverse effects occur frequently during treatment, they tend to run a manageable clinical course under routine clinical observation and medical monitoring.

Lumbar spinal stenosis represents a prevalent degenerative disorder where age-related changes, such as the thickening and protrusion of intervertebral discs, adjacent bones, and the ligamentum flavum, narrow the spinal canal. This progressive structural narrowing causes chronic mechanical compression and local ischemia affecting the cauda equina and spinal nerve roots. Over time, sustained nerve compression and impaired vascular supply precipitate conduction abnormalities characterized by demyelination and axonal degeneration. Patients affected by these structural impairments frequently develop severe gait disturbances and debilitating peripheral neuropathic pain, primarily manifesting as radiating leg pain. Clinical management in Japan often combines standard nonsteroidal anti-inflammatory medications with gabapentinoids, such as pregabalin or mirogabalin, to address neuropathic discomfort when conservative therapies are indicated.

Mirogabalin besylate functions pharmacologically as a selective ligand for the alpha-2-delta auxiliary subunit of voltage-gated calcium channels. It has gained regulatory approval in Japan for managing neuropathic pain following extensive phase 3 clinical evaluations. In the original 12-week MiroTAS trial, adding mirogabalin to ongoing anti-inflammatory regimens achieved superior reductions in leg pain and broader improvements in patient-reported quality of life compared with anti-inflammatory drugs alone. However, clinical implementation of gabapentinoid pharmacotherapy requires navigating known adverse drug reactions, notably dizziness, somnolence, peripheral edema, and generalized edema. While earlier investigations confirmed that mirogabalin provided pain relief regardless of underlying demographic characteristics, questions persisted regarding how clinicians should navigate symptom severity, dosing changes, and prospective resolution once adverse drug reactions emerge.

The study protocol evaluated a modified intention-to-treat set of 214 patients and a safety analysis population comprising 216 patients. Within the safety population, 110 participants received add-on mirogabalin while 106 received nonsteroidal anti-inflammatory drugs alone. Baseline clinical characteristics remained balanced across both treatment arms: participants exhibited a mean age of 67.8 years in the add-on arm and 70.9 years in the monotherapy arm, with female proportions of 54.5 percent and 49.0 percent, respectively. Renal function assessments showed mean creatinine clearance values of 81.5 milliliters per minute in the add-on cohort and 70.7 milliliters per minute in the monotherapy group. Participants had experienced physician-diagnosed radicular-type lumbar spinal stenosis for at least three months, continued stable nonsteroidal anti-inflammatory drug regimens for four weeks or longer, and presented baseline visual analogue scale leg pain scores exceeding 40 millimeters on a 100-millimeter evaluation scale.

Patients assigned to active combination therapy initiated oral mirogabalin at a starting dose of 5 milligrams twice daily during the initial two weeks, escalating to 10 milligrams twice daily during weeks three and four. From week five through week 12, treating physicians maintained the 10-milligram twice-daily regimen or increased the dosage to 15 milligrams twice daily based on individual patient tolerance, while participants with moderate renal impairment received half of each standard scheduled dose. Throughout this treatment trajectory, adverse reactions were cataloged using standardized medical coding. Durations for each reaction were determined from the date of initial symptom onset to the recorded date of clinical recovery or physician confirmation of improvement. The primary analytical objective centered on documenting specific event frequencies, calculating resolution intervals, and tabulating corresponding adjustments to daily mirogabalin dosing schedules.

Among participants receiving add-on mirogabalin, clinical investigators documented 33 distinct events of dizziness, 35 events of somnolence, 6 events of peripheral edema, and 2 events of generalized edema. Overall resolution profiles showed that 27 of the 33 dizziness events, representing 81.8 percent, and 25 of the 35 somnolence events, representing 71.4 percent, either recovered completely or showed substantial clinical improvement. For peripheral edema, 3 of 6 recorded events, or 50.0 percent, recovered or improved, while both reported instances of generalized edema, representing 100.0 percent, resolved. Specifically, dizziness events were classified as recovered in 20 instances, improved in 7, and not recovered in 6. For somnolence, 18 events achieved full recovery, 7 showed clinical improvement, and 10 were categorized as not recovered by the conclusion of the study period.

Time-to-resolution analyses revealed noticeable differences in duration profiles between the two most common adverse drug reactions. For dizziness, symptom duration clustered heavily within the initial 1 to 10 days following onset, yielding a median time from onset to full recovery of 8.0 days, with an interquartile range spanning 2.0 to 20.5 days. Conversely, somnolence exhibited a broader distribution of duration intervals, clustering most frequently across 1 to 10 days and 61 to 70 days. The median time to recovery for somnolence stood at 33.5 days, with an interquartile range between 14.0 and 62.0 days. In contrast to these central neurological symptoms, peripheral edema and generalized edema exhibited no distinct temporal clustering patterns, although the aggregate number of swelling events remained small across the cohort.

The study also examined physician management strategies and patient outcomes stratified by symptom severity and dose adjustments. Among mild dizziness and somnolence events, treatment continued without any dose modification in 75.0 percent and 82.1 percent of instances, respectively. When physicians maintained constant dosing without reduction, favorable outcomes remained high, with 76.2 percent of dizziness events and 70.8 percent of somnolence events recovering or improving. Implementing dose reductions produced even higher recovery and improvement rates, reaching 88.9 percent for dizziness and 75.0 percent for somnolence. When evaluating moderate symptoms, 80.0 percent of moderate dizziness events and 85.7 percent of moderate somnolence events recovered or improved, showing that higher initial symptom severity did not preclude favorable resolution under appropriate clinical supervision.

In parallel with safety profiles, researchers evaluated whether the duration of underlying spinal stenosis or leg pain influenced the degree of pain relief achieved at week 12. Using linear mixed models for repeated measures and Spearman rank correlation coefficients, investigators analyzed changes in visual analogue scale scores relative to disease history. In the mirogabalin add-on group, change in leg pain demonstrated a weak positive correlation with lumbar spinal stenosis duration, yielding a correlation coefficient of 0.2401 and a statistically significant P-value of 0.0269 across 85 evaluable patients. In contrast, correlation between leg pain change and the reported duration of leg pain did not achieve statistical significance in the mirogabalin add-on arm, exhibiting a coefficient of 0.1835 and a P-value of 0.0928, whereas weak positive correlations appeared across both measures within the monotherapy cohort.

The investigators emphasized several methodological limitations inherent to their findings, noting that the research was a retrospective post hoc analysis conducted on a trial designed primarily to establish comparative efficacy rather than adverse event kinetics. Recorded onset and resolution dates depended on entries within an electronic capture database, and when exact onset or improvement dates could not be verified directly, the date of physician confirmation served as an operational proxy, potentially introducing measurement discrepancies. Additionally, because protocol instructions did not standardize the documentation of recurrent events of the same symptom, reporting variations among participating centers could not be ruled out. Finally, because the enrolled population comprised exclusively adult patients diagnosed with radicular lumbar spinal stenosis, the observed recovery intervals and correlation patterns cannot be automatically generalized to other neuropathic pain etiologies without further prospective investigation.

Subject of Research: Clinical course and resolution of mirogabalin-related adverse drug reactions in patients with lumbar spinal stenosis

Article Title: Clinical Outcomes after Onset of Mirogabalin-Related Adverse Drug Reactions in Patients with Lumbar Spinal Stenosis: Post Hoc Analysis of the MiroTAS Study

Article References: Nikaido, T., Shiosakai, K., & Sakoda, H. (2026). Clinical Outcomes after Onset of Mirogabalin-Related Adverse Drug Reactions in Patients with Lumbar Spinal Stenosis: Post Hoc Analysis of the MiroTAS Study. Pain and Therapy, 15(5), 1433-1445. https://doi.org/10.1007/s40122-026-00855-6

Image Credits: AI Generated

DOI: 10.1007/s40122-026-00855-6

Keywords: mirogabalin, lumbar spinal stenosis, adverse drug reactions, MiroTAS study, dizziness, somnolence, gabapentinoids, neuropathic pain, peripheral neuropathic pain, clinical outcomes, post hoc analysis, pain management, radicular pain, NSAIDs add-on, calcium channel alpha-2-delta ligand, creatinine clearance, visual analogue scale

News Source: Ophelia Keating. (November 19, 2026). Mirogabalin Side Effects in Spinal Stenosis Resolved in Most Trial Patients. Scienmag.

Tags: adverse drug reactionscalcium channel alpha-2-delta ligandclinical outcomescreatinine clearancedizzinessGabapentinoidslumbar spinal stenosismirogabalinMiroTAS studyneuropathic painNSAIDs add-onPain Managementperipheral neuropathic painpost hoc analysisradicular painsomnolenceVisual Analogue Scale
Share12Tweet7Share2ShareShareShare1

Related Posts

Three-Dimensional Ultrasound Reveals Bilateral Muscle Thinning in Chronic Stroke Survivors

Three-Dimensional Ultrasound Reveals Bilateral Muscle Thinning in Chronic Stroke Survivors

November 20, 2026
Review Outlines Transcriptional Dependence and Preclinical Vulnerabilities in Supratentorial Ependymoma

Review Outlines Transcriptional Dependence and Preclinical Vulnerabilities in Supratentorial Ependymoma

November 20, 2026

Dental Remineralization Trials Rely Heavily on Combined In Vivo Assessment Techniques

November 20, 2026

Adjunctive Manual Root Planing Enhances Ultrasonic Debridement Outcomes in Severe Periodontitis

November 20, 2026

POPULAR NEWS

  • Pressurized Isopropanol Extracts Antioxidants and Enzyme Inhibitors From Prickly Pear Seeds

    Pressurized Isopropanol Extracts Antioxidants and Enzyme Inhibitors From Prickly Pear Seeds

    29 shares
    Share 12 Tweet 7
  • Integrated Photonic Quantum Converter Enhances Digital Phase Estimation in Metrology

    29 shares
    Share 12 Tweet 7
  • Endoscopic Ultrasound Expands Diagnostic and Guided Interventional Roles in Pancreatic Disease

    29 shares
    Share 12 Tweet 7
  • Full-Length TDP-43 Protein Propagates From Motor Cortex to Muscle in Rats

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Three-Dimensional Ultrasound Reveals Bilateral Muscle Thinning in Chronic Stroke Survivors

Physicists Derive Gauge-Independent Scalar Effective Field Equations on de Sitter Background

Native Cladoceran Shows Greater Sensitivity to Imidacloprid Than Exotic Water Fleas

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.